GAIN THERAPEUTICS INC. - COMMON STOCK

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

26 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024

19 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference

03 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

29 أغسطس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

08 أغسطس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference

01 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

09 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

28 يونيو 2024 16:39:04 بحسب Nasdaq GlobeNewswire

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

27 يونيو 2024 16:08:08 بحسب Nasdaq GlobeNewswire

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease

27 يونيو 2024 08:35:48 بحسب Nasdaq GlobeNewswire

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

25 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

13 يونيو 2024 21:00:59 بحسب Nasdaq GlobeNewswire

Gain Therapeutics Announces Proposed Public Offering

13 يونيو 2024 16:44:54 بحسب Nasdaq GlobeNewswire

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

30 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

14 مايو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

24 أبريل 2024 09:25:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

08 أبريل 2024 09:25:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

01 أبريل 2024 09:25:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

26 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Gain Therapeutics to Present at Public Ventures Discovery Day

15 مارس 2024 14:30:34 بحسب Nasdaq GlobeNewswire